Natera, Inc. (NASDAQ:NTRA – Get Free Report) Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Natera Price Performance
Natera stock traded up $9.35 during mid-day trading on Tuesday, reaching $222.82. The stock had a trading volume of 1,209,573 shares, compared to its average volume of 1,440,794. The company has a market capitalization of $31.91 billion, a price-to-earnings ratio of -136.70 and a beta of 1.56. The company has a 50-day moving average price of $205.34 and a two-hundred day moving average price of $216.16. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36.
Wall Street Analyst Weigh In
NTRA has been the subject of several analyst reports. Wolfe Research initiated coverage on shares of Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. JPMorgan Chase & Co. upped their price target on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wells Fargo & Company upped their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.12.
Institutional Trading of Natera
Hedge funds and other institutional investors have recently bought and sold shares of the business. Reflection Asset Management purchased a new stake in Natera in the fourth quarter worth $29,000. Palladiem LLC purchased a new stake in Natera in the fourth quarter worth $31,000. Horizon Investments LLC purchased a new stake in Natera in the third quarter worth $32,000. International Assets Investment Management LLC increased its stake in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust increased its stake in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
- Five stocks we like better than Natera
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
